{"database":"biostudies-arrayexpress","file_versions":[],"scores":null,"additional":{"submitter":["Kevin Schmidt"],"organism":["Rattus norvegicus"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/E-MTAB-16035"],"description":["This study aims to explore the therapeutic potential of the cysteine protease inhibitor aloxistatin (E64d) as a candidate to combat cardiac fibrotic progression. Rodent living myocardial slices (LMS) from left ventricular tissue were treated for 4h and 24h with aloxistatin (100µM) or DMSO control. For RNA isolation from LMS, LMS were transferred into 2ml vials containing ceramic beads and QiAzol Lysis reagent and tissue was homogenized utilizing the Precellys Evolution. RNA isolation was performed based on phenol-chloroform-extraction method."],"repository":["biostudies-arrayexpress"],"sample_protocol":["Sample Collection - LMS were transferred into 2ml vials containing ceramic beads and QiAzol Lysis reagent and tissue was homogenized utilizing the Precellys Evolution.","Sequencing - Illumina (NovaSeq X Plus) platform was used for paired end 150 bp sequencing (40 M reads per sample). Sequencing was done by Novogene.","Library Construction - rRNA depletion library preparation was performed by Novogene","Nucleic Acid Extraction - RNA isolation was performed based on phenol-chloroform-extraction method."],"figure_sub":["Organization","MINSEQE Score","Assays and Data","Processed Data","MAGE-TAB Files"],"data_protocol":["Sequence Alignment - mapping to GRCr8 with STAR aligner using default parameters","Data Transformation - DESeq2 pipeline (for R) was used for count normalization and DEG calculation with default parameters"],"omics_type":["Metabolomics","Unknown","Transcriptomics","Genomics","Proteomics"],"instrument_platform":["Illumina NovaSeq X"],"study_type":["RNA-seq of total RNA"],"species":["Rattus norvegicus"],"pubmed_authors":["Jan Fiedler","Maria Jordan","Kevin Schmidt"],"additional_accession":[]},"is_claimable":false,"name":"Total RNA-seq of rat living myocardial slices (LMS) treated with aloxistiatin (E64d)","description":"This study aims to explore the therapeutic potential of the cysteine protease inhibitor aloxistatin (E64d) as a candidate to combat cardiac fibrotic progression. Rodent living myocardial slices (LMS) from left ventricular tissue were treated for 4h and 24h with aloxistatin (100µM) or DMSO control. For RNA isolation from LMS, LMS were transferred into 2ml vials containing ceramic beads and QiAzol Lysis reagent and tissue was homogenized utilizing the Precellys Evolution. RNA isolation was performed based on phenol-chloroform-extraction method.","dates":{"release":"2026-07-06T00:00:00Z","modification":"2026-07-06T15:04:25.45Z","creation":"2025-11-13T15:02:57.73Z"},"accession":"E-MTAB-16035","cross_references":{"ENA":["ERP183923"],"EFO":["EFO_0002944","EFO_0004170","EFO_0009653","EFO_0004917","EFO_0005518","EFO_0003816","EFO_0004184"]}}